In this edition, lung cancer screening critically low across the U.S, first in-human CRISPR test with gene replacement, racial and economic segregation linked to higher cancer mortality rates, and more. Read the full coverage here: Lung cancer screening rates in US 'simply unacceptable' First CRISPR-based cell therapy to use gene replacement feasible, safe for solid tumors Racial, economic segregation linked to cancer mortality Onivyde regimen extends OS in metastatic pancreatic ductal adenocarcinoma Immunotherapy a 'significant improvement' for treatment of multiple myeloma References: Davies FE, et al. New therapeutic agents for relapsed/refractory multiple myeloma: CAR T and bispecific antibodies. Presented at: 40th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow; Nov. 9-11, 2022. Foy SP, et al. Abstract 1478. Presented at: Society for Immunotherapy of Cancer Annual Meeting; Nov. 8-12, 2022; Boston. Press Release Press Release Zhang L, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.5382.

Ver todos los episodios